Conflict of interests
EPS
ONCOLOGY
TS: speaker fees from Eli Lilly, Chugai, Taiho, and Boehringer Ingelheim; research grants from Novartis, Eli Lilly, Daiichi-Sankyo, AbbVie, Bristol-Myers Squibb, Eisai, AstraZeneca, Pfizer, Loxo Oncology, Takeda Oncology, Incyte, Chordia Therapeutics, 3D-Medicine, SymBio, PharmaMar, Five Prime, and Astellas; and advisory board fees from AbbVie, Daiichi-Sankyo, and Takeda Oncology. KN: speaker’s fees from Astellas, Takeda, Nanzando, AstraZeneca, Chugai, Roche Diagnostics, MSD, Eli Lilly, Nippon Kayaku, Ono, Merck Biopharma, Bayer, Daiichi Sankyo, Novartis, Kyowa Kirin, Taiho, Pfizer, AbbVie, Bristol Myers Squibb, CareNet, Amgen, Medical Review, Yodosha, 3H Clinical Trial, Thermo Fisher, Hisamitsu, Nichi-Iko, Kyorun, Medicus Shuppan, Nippon Boehringer Ingelheim, Nikkei Business, Yomiuri Telecasting and Medical Mobile; research grants from MSD, AstraZeneca, Pfizer, Icon, Astellas, Bayer, Takeda, Novartis, Eli Lilly, EPS, Bayer, Bristol Myers Squibb, CMIC Shift Zero, PRA HEALTHSCIENCES, Taiho, Eisai, Merck Biopharma, PAREXEL, Mochida, Covance, Ono, Kissei, Medical Research Support, Sysmex, GlaxoSmithKline, Sanofi, A2 Healthcare, Kyowa Hakko Kirin, Syneos Health, AbbVie Inc. EPS, Pfizer R&D, Chugai, Daiichi Sankyo, PPD-SNBL, Nippon Boehringer Ingelheim, IQVIA, Quintiles, Clinical Research and SymBio; consulting fees from Astellas, Takeda, Eli Lilly, Pfizer, KYORIN and Ono. HH: speaker fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eli Lilly, Kyorin, Merck Biopharma, MSD, Novartis, Ono, Shanghai Haihe Biopharm, Taiho, and Takeda; research grants from AstraZeneca, Boehringer Ingelheim, Chugai, and Ono; advisory board fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eli Lilly, Pfizer, Shanghai Haihe Biopharm, Takeda, and Merck Biopharma. TI: No conflict of interest. HK: speaker fees from Glaxo Smith Kline, Bristol-Myers Squibb, Eli Lilly, MSD, Ono, Chugai, Takeda, and Taiho; research grants from Chugai, Taiho, Kobayashi, and Eisai; consulting fees from Bristol-Myers Squibb, Eli Lilly, MSD, Ono, Daiichi-Sankyo, and Taiho; and honoraria from Bristol-Myers Squibb, AstraZeneca, Bayer, Eli Lilly, MSD, Ono, Chugai, Daiichi Sankyo, Merck Biopharma, Takeda, Yakult, and Taiho. SW: No conflict of interest. NY: speaker fees from AstraZeneca, Pfizer, Eli Lilly, ONO, Chugai, Sysmex, Daiichi-Sankyo, and Eisai; research grants from Astellas, Chugai, Eisai, Taiho, Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka, Carna Biosciences, and Genmab; and advisory board fees from Eisai, Takeda, Otsuka, Boehringer Ingelheim, Cimic, and Chugai. KY: speaker fees from Eisai, Astrazeneca, Pfizer, Eli Lilly, Fuji Film, Chugai, Taiho, and Takeda; research grants from Daiichi Sankyo, Eisai, AstraZeneca, Pfizer, Eli Lilly, Fuji Film, Chugai, Taiho, Takeda, Sanofi, Genmab, Ono, Novartis, Boeringer Ingelheim, MSD, Seagen, and Nihon-Kayaku; and advisory board fees from Ono, Genmab, Novartis, Eisai, Chugai, Takeda, Daiichi Sankyo, and MSD. TK: Speaker’s fees from Sysmex and Chugai; research grants from PACT Pharma. JS: Speaker fees from AstraZeneca and Chugai. KT: Research grants from Pfizer, Eisai, Daiich-Sankyo, and Chugai. MT: Speaker fees from AstraZeneca, ONO, Chugai Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim. KK, KA, and ST are full-time employees of SymBio Pharmaceuticals, Ltd..